136235-11-5

Basic information

• Product Name: (S)-2-[[[(4-methylphenyl)sulfonyl]oxy]methyl]-1-pyrrolidinecarboxylic acid,1,1-dimethylethyl ester
• Synonyms: (S)-2-[[[(4-methylphenyl)sulfonyl]oxy]methyl]-1-pyrrolidinecarboxylic acid,1,1-dimethylethyl ester
• CAS NO: 136235-11-5
• Molecular Weight: 355.455
• Mol File: 136235-11-5.mol

Chemical Properties

• CAS DataBase Reference: (S)-2-[[[(4-methylphenyl)sulfonyl]oxy]methyl]-1-pyrrolidinecarboxylic acid,1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-[[[(4-methylphenyl)sulfonyl]oxy]methyl]-1-pyrrolidinecarboxylic acid,1,1-dimethylethyl ester(136235-11-5)
• EPA Substance Registry System: (S)-2-[[[(4-methylphenyl)sulfonyl]oxy]methyl]-1-pyrrolidinecarboxylic acid,1,1-dimethylethyl ester(136235-11-5)

Safety Data

• Hazardous Substances Data: 136235-11-5(Hazardous Substances Data)

Upstream product

• 69610-40-8 N-(tert-butoxycarbonyl)-L-prolinol 
• 98-59-9 p-toluenesulfonyl chloride 
• 498-63-5 2-hydroxymethylpyrrolidine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 145681-01-2 (+/-)-N-tert-butoxycarbonylproline methyl ester 
• 15761-39-4 N-tert-butoxycarbonyl-proline 
• 170491-63-1 N-Boc-prolinol 

Downstream Products

• 1160561-85-2 N-Boc-2-(phenylthiomethyl)pyrrolidine 
• 1146960-77-1 tert-butyl 2-[(2-tert-butylphenoxy)methyl]pyrrolidine-1-carboxylate 
• 29079-30-9 6-(4-methoxyphenyl)-7-methyl-1,2,3,5,8,8a-hexahydroindolizine 
• 26294-41-7 4-[7-methyl-1,2,3,5,8,8a-hexahydroindolizin-6-yl]phenol 
• 1353971-02-4 2-(((1-(tert-butoxycarbonyl)pyrrolidin-2-yl)methyl)thio)acetic acid 

Relevant articles and documents

Inexpensive multigram-scale synthesis of cyclic enamines and 3-N spirocyclopropyl systems

Cyclic enamines are important synthons for many synthetic and pharmacological targets. Here, we report an inexpensive, catalyst-free, multigram-scale synthesis for cyclic enamines with exocyclic double bonds and four- to seven-membered rings. This strategy is more conducive to scale up, permissive of functionalization around the cyclic system, and less sensitive to the nature of the N-protecting group than previously-described methods for cyclic enamine synthesis. Further, we explore application of these enamines to the synthesis of highly-strained spirocyclic 3N-cyclopropyl scaffolds.

Nitrogen-substituted six-membered aromatic heterocyclic ketone compound as well as pharmaceutical composition, preparation method and application thereof

The invention relates to a nitrogen-substituted six-membered aromatic heterocyclic ketone compound as well as a pharmaceutical composition, a preparation method and an application thereof. The invention particularly discloses nitrogen-substituted six-membered aromatic heterocyclic ketones shown as a general formula I, or pharmaceutically acceptable salts, prodrugs, isomers, racemates, precursors or solvates of the nitrogen-substituted six-membered aromatic heterocyclic ketones. The six-membered nitrogen-containing aromatic heterocyclic ketone compound disclosed by the invention is an efficientand high-selectivity BRD4 inhibitor; the compound has a good treatment effect on arthritis, autoimmune diseases or breast cancer, brain cancer, cervical cancer, colorectal cancer, gastrointestinal cancer, esophageal cancer, liver cancer, lung cancer, pancreatic cancer, endometrial cancer, nasopharyngeal carcinoma, ovarian cancer, prostate cancer, hematogenic system tumor and other diseases. The invention also discloses a preparation method and an application of the compound as shown in the general formula I.

SMARCA INHIBITORS AND USES THEREOF

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same for the modulation of one or more SWI/SNF-related matrix associated actin dependent regulator of chromatin subfamily A (SMARCA) and/or polybromo-1 (PB-1) protein via ubiqitination and/or degradation by compounds. The compounds are useful in treatment of cancer.

Structure-activity relationship studies of (E)-3,4-dihydroxystyryl alkyl sulfones as novel neuroprotective agents based on improved antioxidant, anti-inflammatory activities and BBB permeability

(E)-3,4-dihydroxystyryl alkyl sulfones, as new analogues of neurodegenerative agents, were designed and synthesized. The biological results demonstrated that most of the target compounds preserved antioxidant and anti-inflammatory potency in scavenging reactive free radicals, protecting neuronal cells against neurotoxins such as H2O2, 6-hydroxydopamine and inhibiting lipopolysaccharide (LPS)-induced over-production of NO. Among these compounds, 6.22 with cyclopentyl propyl exhibited prominent antioxidant activity at low concentration (2.5 μM) in H2O2 model (cell viability = 94.5%). In addition, 6.22 (IC50 = 1.6 μM) displayed better anti-inflammatory activity than that of lead compound 1 (IC50 = 13.4 μM). In view of the outstanding performance of 6.22, the apoptotic rates of H2O2-damaged PC12 cells were detected by Annexin V-FITC/PI assay. 6.22 showed higher potency in inhibition of apoptosis than 1 at low concentration (2.5 μM), consisting with the antioxidant and anti-inflammatory models. Furthermore, with the predicted CNS (+) blood-brain barrier (BBB) permeability (Pe = 6.84 × 10?6 cm s?1), low cytotoxicity and favorable physiochemical properties based on calculation, compound 6.22 can be further developed as a potential multifunctional neuroprotective agent.

AMINOPYRIDINE COMPOUNDS AND METHODS FOR THE PREPARATION AND USE THEREOF

The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A/B (Rgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I and Formula III, as described herein, and pharmaceutically acceptable salts thereof.

Synthesis of (+)-Ipalbidine Based on 6-exo-trig Radical Cyclization of a β-Amino Radical

N-Boc (S)-proline was converted into (2S)-2-[(phenylselanyl)methyl]pyrrolidine, which was alkylated on nitrogen with 2-bromo-1-(4-methoxyphenyl)ethan-1-one. Reaction with vinyllithium, 6-exo-trig radical cyclization (Bu3SnH, AIBN, PhMe, 110 °C), dehydration (P2O5, H3PO4), and demethylation (BBr3) gave (+)-ipalbidine with ee >99%.

HETEROCYCLIC COMPOUND

The present invention relates to wherein each symbol is as defined in the specification. The compound of the present invention has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of disease and condition mediated by increased RBP4.

Base-catalysed intramolecular hydroamination of vinyl sulfiies

Small amounts of n-butyllithium catalyse the highly efficient hydroamination of a large variety of vinyl sulfides. This novel methodology offers an easy access to a wide range of nitrogen heterocycles, including simple pyrrolidines and piperidines, as well as more complex bicyclic compounds. Subsequent transformations of the sulfur group led to the formation of functionalised alkaloid-like substructures. Wiley-VCH Verlag GmbH & Co. KGaA.

VLA-4 inhibitor compounds

Compounds that selectively inhibit the binding of ligands to alpha4beta1 integrin (VLA-4) and methods for their preparation are disclosed. In one embodiment, compounds of the invention are represented by Formula I: As selective inhibitors of VLA-4 mediated cell adhesion, compounds of the present invention are useful in the treatment of conditions associated with such adhesion, including, but not limited to, such conditions as inflammatory and autoimmune responses, diabetes, asthma, psoriasis, inflammatory bowel disease, transplantation rejection, and tumor metastasis. Also disclosed are pharmaceutical compositions, methods of inhibiting VLA-4 mediated cell adhesion and methods of treating conditions associated with LA-4 mediated cell adhesion, which involve compounds of Formula I.